Company intelligence / Profile preview
Cinkate
Suzhou, Jiangsu, Chinacinkate.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cinkate developed and commercialized AIROHUA (leflunomide) for rheumatoid arthritis, achieving the first domestic launch in China with subsequent indications in immunology and related fields. Their tenofovir prodrug asset (AGX-1009) and hydroxychloroquine have been in development, but no recent pivotal data on new clinical products available.
- Therapeutic areas
- ImmunologyEndocrinologyNephrologyInfectious DiseasesHematology
- Modalities
- Small moleculeHerbal medicine
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Institute of Medicinal Biotechnology (China)Institute of Pharmacology and Toxicology of the Academy of Military Medical Sciences (China)Institute of Radiation Medicine of the Academy of Military Medical Sciences (China)HongHui MeditechChangzheng Pharmaceutical Factory
Beyond the preview
Go deeper on Cinkate.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cinkate.